Pediatric Mortality at Pediatric versus Adult Trauma Centers

Mazhar Khalil1, Ghayth Alawwa1, Frederique Pinto1

  • 1Department of Surgery, Brookdale Hospital and Medical Center, Brooklyn, New York, USA.

Insights

Severely injured young children (0-14 years) show improved emergency department survival at pediatric trauma centers (PTCs) compared to adult trauma centers (ATCs). Adolescents did not demonstrate a significant difference in outcomes between center types.

Area of Science:

  • Trauma Surgery
  • Pediatric Critical Care
  • Health Services Research

Background:

  • Pediatric trauma centers (PTCs) were established to improve outcomes for injured children.
  • Previous studies on the effectiveness of PTCs have yielded conflicting results.
  • This study aims to clarify the impact of PTCs on pediatric trauma outcomes.

Purpose of the Study:

  • To determine if severely injured children ≤ 14 years have better outcomes at PTCs compared to adult trauma centers (ATCs).
  • To investigate if improved survival at PTCs is associated with higher emergency department (ED) survival rates.

Main Methods:

  • Retrospective analysis of severely injured children (ISS > 15) aged ≤ 18 years from the National Trauma Data Bank (NTDB) (2011-2012).
  • Stratification into two age cohorts: young children (0-14 years) and adolescents (15-18 years).
  • Primary outcomes included ED and in-patient (IP) mortality; secondary outcomes comprised complications, length of stay, and ventilator days.

Main Results:

  • In multivariate analysis, children ≤ 14 years had significantly lower ED (OR 0.42) and IP mortality (OR 0.73) at PTCs compared to ATCs.
  • No significant differences in ED or IP mortality were observed for adolescents (15-18 years) between PTCs and ATCs.
  • Children treated at PTCs had more ICU and ventilator-free days and were more likely to be discharged home.

Conclusions:

  • Young children (≤ 14 years) benefit from improved ED survival when treated at PTCs compared to ATCs.
  • Adolescents (15-18 years) do not show a significant difference in mortality outcomes between PTCs and ATCs.
  • PTCs appear to facilitate better recovery trajectories for young pediatric trauma patients.
Abstract

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
341
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
24
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
35
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
31
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
21